Skip to main content
Premium Trial:

Request an Annual Quote

Almac Collaborating with Oxford University to Develop Gene Signature for Ductal Carcinoma Recurrence

NEW YORK (GenomeWeb News) - Cancer diagnostics developer Almac Diagnostics said today it is undertaking a collaborative study with Oxford University that will seek to create a gene signature to predict the recurrence of ductal carcinoma in situ, a type of breast cancer.
 
The study will use the company’s Breast Cancer DSA microarray to help generate a gene expression signature that would be used to identify patients who are likely to experience a recurrence of DCIS.
 
Isolating patients at such a risk could be used to help doctors and patients make important treatment decisions, the company said. Total mastectomy may be completely curative for some DCIS patients, but may be over-treatment in other cases, so a diagnostic that would separate those groups could help some patients who face less likelihood of recurrence decide to opt for more conservative procedures.
 
Almac, based in Craigavon, Northern Ireland, said it will use paraffin-embedded samples for the study and will employ its bioinformatics team to “interrogate the resulting data to identify a potential signature.” Almac will conduct the research with Adrian Harris of Cancer Research UK and a professor of medical oncology at the University of Oxford.
 
In addition to its breast cancer DSA, Almac also markets a Colorectal Cancer DSA and a Lung Cancer DSA. Diagnostic tools for ovarian cancer and for prostate cancer will be launched later in 2008, the company said.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.